Viability of pegIFNα-RBV for CHC in the direct acting antiviral era: a practical algorithm between efficacy and cost containment

References

• Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975–82.10.1056/NEJMoa020047
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355:2444–51.10.1056/NEJMct061675
   PubMed Web of Science ®Google Scholar
• A special meeting review edition: advances in the treatment of hepatitis C virus infection from EASL 2012. Gastroenterol Hepatol (NY). 2012 Jun; 8( 6 Suppl 3): 1–20.
   Google Scholar
• Tovo CV, de Mattos AA, de Almeida PR. Chronic hepatitis C genotype 1 virus: who should wait for treatment? World J Gastroenterol. 2014 Mar 21;20(11):2867–75.10.3748/wjg.v20.i11.2867
   PubMed Web of Science ®Google Scholar
• Cortesi PA, Ciaccio A, Rota M, Lim JK, De Salvia S, Okolicsanyi S, et al. Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. J Viral Hepatitis. 2015 Feb;22(2):175–83.10.1111/jvh.12278
   PubMed Web of Science ®Google Scholar
• Kronenberger B, Herrmann E, Micol F, von Wagner M, Zeuzem S. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. Hepatology. 2004 Dec;40(6):1442–9.10.1002/(ISSN)1527-3350
   PubMed Web of Science ®Google Scholar
• Lindh M, Alestig E, Arnholm B, Eilard A, Hellstrand K, Lagging M, et al. Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection. J Clin Microbiol. 2007 Aug;45(8):2439–45.10.1128/JCM.00577-07
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Zampino R, Portella G, Adinolfi LE, Utili R, Ruggiero G. Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. Clin Infect Dis. 2009 Aug 15;49(4):498–506.10.1086/599188
   PubMed Web of Science ®Google Scholar
• Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetics studies. J Antimicrob Chemother. 2004 Jan;53(1):15–8.
   PubMed Web of Science ®Google Scholar
• Deltenre P, Corouge M, Canva V, Castel H, Wartel F, Dharancy S, et al. Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin. J Hepatol. 2011 Nov;55(5):989–95.10.1016/j.jhep.2011.02.014
   PubMed Web of Science ®Google Scholar
• Knop V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, et al. Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. Ann Hepatol. 2013 Mar–Apr;12(2):190–8.
   PubMed Web of Science ®Google Scholar
• Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998 Oct 2;282(5386):103–7.10.1126/science.282.5386.103
   PubMed Web of Science ®Google Scholar
• Layden-Almer JE, Cotler SJ, Layden TJ. Viral kinetics in the treatment of chronic hepatitis C. J Viral Hepat. 2006 Aug;13(8):499–504.10.1111/jvh.2006.13.issue-8
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013 May 16;368(20):1867–77.10.1056/NEJMoa1214854
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Dusheiko GM, Salupere R. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial [AASLD abstract 1085]. Hepatology. 2013;58(4):733A.
   Web of Science ®Google Scholar
• Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013 May;13(5):401–8.10.1016/S1473-3099(13)70033-1
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013 May 16;368(20):1878–87.10.1056/NEJMoa1214853
   PubMed Web of Science ®Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015 Apr;61(4):1127–35.10.1002/hep.v61.4
   PubMed Web of Science ®Google Scholar
• Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Dvory-Sobol H, et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology. 2015 Mar;61(3):769–75.10.1002/hep.v61.3
   PubMed Web of Science ®Google Scholar
• Reau NS, Jensen MD. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014 Apr;59(4):1246–9.10.1002/hep.27039
   PubMed Web of Science ®Google Scholar
• Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001 Jun;33(6):1358–64.10.1053/jhep.2001.24432
   PubMed Web of Science ®Google Scholar
• Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005 Aug 18;436(7053):967–72.10.1038/nature04082
   PubMed Web of Science ®Google Scholar
• Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988 Jun 3;240(4857):1285–93.10.1126/science.3287615
   PubMed Web of Science ®Google Scholar
• Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015;149:1462–70.10.1053/j.gastro.2015.07.043
   PubMed Web of Science ®Google Scholar
• Andriulli A, Di Marco V, Margaglione M, Ippolito AM, Fattovich G, Smedile A, et al. Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. J Hepatol. 2014 Jan;60(1):16–21.10.1016/j.jhep.2013.07.040
   PubMed Web of Science ®Google Scholar
• Fujino T, Nakamuta M, Aoyagi Y, Kohjima M, Satoh T, Fukuda M, et al. Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNα2a shows earlier viral decline than peg-IFNα2b in combination therapy with ribavirin. Med Sci Monit. 2011 Dec;17(12):CR687–91.
   Web of Science ®Google Scholar
• Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010 Jan;138(1):116–22.10.1053/j.gastro.2009.10.005
   PubMed Web of Science ®Google Scholar
• Lindh M, Lagging M, Arnholm B, Eilard A, Nilsson S, Norkrans G, et al. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. J Viral Hepat. 2011 Jul;18(7):e325–31.10.1111/jvh.2011.18.issue-7
   PubMed Web of Science ®Google Scholar
• Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. Scand J Gastroenterol. 2007 Feb;42(2):247–55.10.1080/00365520600955526
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000 Dec 7;343(23):1666–72.10.1056/NEJM200012073432301
   PubMed Web of Science ®Google Scholar
• Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. 2003 Sep;38(3):639–44.10.1053/jhep.2003.50350
   PubMed Web of Science ®Google Scholar